CA
NZ
UK
AU
IND
US
● Biodexa received $2.3 million in gross proceeds from aWarrantexercise on September 15, 2026, alongside going-concern warnings.
BioMarin (NASDAQ:BMRN), the San Rafael, California rare disease drugmaker founded in 1997 andMarketingnine therapies, is slipping in Friday's session even after presenting five-year Phase 3 extension data for Pombiliti plus Opfolda in late-onset Pompe disease at the World Muscle Society Congress. The shares are …
GRAIL (NASDAQ:GRAL), the Menlo Park, California company behind the Galleri blood test that screens asymptomatic adults over 50 for multiple cancers, is rebounding in Friday's session after a sharp pullback in the prior session. The shares are up 6.73% at $141.48, while the healthcare …
ImmunityBio (NASDAQ:IBRX), the San Diego commercial-stage immunotherapy company whose lead product Anktiva is an IL-15 superagonist approved with BCG for a form of bladder cancer, is surging in Friday's session. The shares are up 9.55% at $10.17 on volume more than double the average …
Kodiak Sciences (NASDAQ:KOD), the Palo Alto, California biopharmaceutical company developing treatments for chronic retinal diseases, is falling in Friday's session. The shares are down 8.74% at $89.86, giving back part of a rally in which the stock rose 178% on September 28 and reached …
Nanobiotix (NASDAQ:NBTX), the Paris-based late-stage biotechnology company developing physics-based cancer treatments, is falling again in Friday's session. The shares are down 7.54% at $25.80, extending a slide of about 10.5% in the prior session, when the Paris listing fell about 8%.
Oscar Health (NYSE:OSCR), the New York-based health insurer that sells Affordable Care Act andMedicareAdvantage plans to more than 3 million members through its own technology platform, is rebounding in Friday's session. The shares are up 3.48% at $30.94 after a roughly 3% drop in …
PACS Group (NYSE:PACS), the Salt Lake CityHolding Companywhose subsidiaries run 355 post-acute facilities across 20 states and serve more than 33,400 patients daily, is rebounding in Friday's session. The shares are up 3.83% at $42.60 on lighter-than-average volume, while the healthcare sector is little …
Qiagen (NYSE:QGEN), the Venlo, Netherlands provider of sample preparation and molecular testing tools for life sciences and diagnostics customers, is jumping in Friday's session on a report that talks with a strategic buyer have advanced. The shares are up 6.85% at $44.92 on above-average …
Addex Therapeutics (NASDAQ:ADXN), a penny stock from a Geneva-based clinical-stage company developing small-molecule allosteric modulators for neurological disorders, is slipping in pre-market trading after announcing executive changes. Shares are at $2.88, down 3.30% from Thursday's close of $2.98, which itself followed a 7.97% gain.
Please wait processing your request...